# OneMedNet Corp: overview ONMD · Nasdaq · CIK 1849380 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/onmd.md) · [Financials](/companies/onmd/financials.md) · [Filings](/companies/onmd/filings.md) · [Insiders](/companies/onmd/insiders.md) Latest reported revenue: [$292.0k](/filings/0001493152-26-038461.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 14, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001493152-26-038461). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [142](/filings/0001493152-25-023544.md) | [26.0 d](/filings/0001493152-26-013681.md) | [137](/filings/0001493152-26-023801.md) | [155](/filings/0001493152-26-038461.md) | [177](/filings/0001493152-25-023544.md) | [891 d](/filings/0001493152-26-013681.md) | [96.0](/filings/0001493152-26-023801.md) | [292](/filings/0001493152-26-038461.md) | | Gross margin | % | [(59.2%)](/filings/0001493152-25-023544.md) | [(100.0%) d](/filings/0001493152-26-013681.md) | [(163.5%)](/filings/0001493152-26-023801.md) | [(155.5%)](/filings/0001493152-26-038461.md) | [(125.4%)](/filings/0001493152-25-023544.md) | [18.5% d](/filings/0001493152-26-013681.md) | [(395.8%)](/filings/0001493152-26-023801.md) | [(193.5%)](/filings/0001493152-26-038461.md) | | Operating margin | % | [(1645.1%)](/filings/0001493152-25-023544.md) | [(10446.2%) d](/filings/0001493152-26-013681.md) | [(1623.4%)](/filings/0001493152-26-023801.md) | [(1331.0%)](/filings/0001493152-26-038461.md) | [(1262.7%)](/filings/0001493152-25-023544.md) | [(345.9%) d](/filings/0001493152-26-013681.md) | [(2658.3%)](/filings/0001493152-26-023801.md) | [(774.3%)](/filings/0001493152-26-038461.md) | | Net margin | % | [(1449.3%)](/filings/0001493152-25-023544.md) | [(9126.9%) d](/filings/0001493152-26-013681.md) | [(1388.3%)](/filings/0001493152-26-038461.md) | [1923.9%](/filings/0001493152-26-038461.md) | [(418.6%)](/filings/0001493152-25-023544.md) | [(352.4%) d](/filings/0001493152-26-013681.md) | [(2555.2%)](/filings/0001493152-26-038461.md) | [(743.8%)](/filings/0001493152-26-038461.md) | | Diluted EPS | $ per share | [(0.07)](/filings/0001493152-25-023544.md) | not reported | [(0.06)](/filings/0001493152-26-023801.md) | [0.07](/filings/0001493152-26-038461.md) | [(0.01)](/filings/0001493152-25-023544.md) | not reported | [(0.04)](/filings/0001493152-26-023801.md) | [(0.04)](/filings/0001493152-26-038461.md) | | Free cash flow | $k | [(1,912) d](/filings/0001493152-25-023544.md) | [(2,031) d](/filings/0001493152-26-013681.md) | [(1,859)](/filings/0001493152-26-023801.md) | [(2,192) d](/filings/0001493152-26-038461.md) | [(1,747) d](/filings/0001493152-25-023544.md) | [(1,718) d](/filings/0001493152-26-013681.md) | [(1,544)](/filings/0001493152-26-023801.md) | [(1,884) d](/filings/0001493152-26-038461.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | | Revenue | $k | [1,153](/filings/0001493152-24-043625.md) | [1,021](/filings/0001641172-25-004815.md) | [643](/filings/0001493152-26-013681.md) | [1,359](/filings/0001493152-26-013681.md) | | Gross margin | % | [(31.2%)](/filings/0001493152-24-043625.md) | [(12.6%)](/filings/0001641172-25-004815.md) | [(43.7%)](/filings/0001493152-26-013681.md) | [(37.0%)](/filings/0001493152-26-013681.md) | | Operating margin | % | [(669.1%)](/filings/0001493152-24-043625.md) | [(671.2%)](/filings/0001641172-25-004815.md) | [(1493.8%)](/filings/0001493152-26-013681.md) | [(711.3%)](/filings/0001493152-26-013681.md) | | Net margin | % | [(2641.0%)](/filings/0001493152-24-043625.md) | [(3308.5%)](/filings/0001641172-25-004815.md) | [(1575.3%)](/filings/0001493152-26-013681.md) | [(206.1%)](/filings/0001493152-26-013681.md) | | Diluted EPS | $ per share | [(7.66)](/filings/0001493152-24-043625.md) | [(4.65)](/filings/0001641172-25-004815.md) | [(0.36)](/filings/0001493152-26-013681.md) | [(0.06)](/filings/0001493152-26-013681.md) | | Free cash flow | $k | [(4,761)](/filings/0001493152-24-043625.md) | [(4,835)](/filings/0001641172-25-004815.md) | [(7,003)](/filings/0001493152-26-013681.md) | [(7,516)](/filings/0001493152-26-013681.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/onmd/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [TORONTO DOMINION BANK](/funds/947263.md) | 2026-06-30 | $102.0k | 2,914,096 | | Added +3,945 | | [EXENCIAL WEALTH ADVISORS, LLC](/funds/1576151.md) | 2026-03-31 | $46.6k | 871,744 | | Not compared | | [Savant Capital, LLC](/funds/1482880.md) | 2026-06-30 | $30.9k | 871,744 | | New +871,744 | | [D. E. Shaw & Co., Inc.](/funds/1009207.md) | 2026-06-30 | $15.2k | 420,000 | | Unchanged | | [Yakira Capital Management, Inc.](/funds/1584639.md) | 2026-06-30 | $11.5k | 330,494 | | Unchanged | | [Polar Asset Management Partners Inc.](/funds/1326389.md) | 2026-06-30 | $9.1k | 256,916 | | Unchanged | | [RIVERNORTH CAPITAL MANAGEMENT, LLC](/funds/1447578.md) | 2026-06-30 | $4.6k | 128,631 | | Unchanged | | [Clear Street Group Inc.](/funds/1881567.md) | 2026-06-30 | $2.9k | 83,747 | | Unchanged | | [WHITEBOX ADVISORS LLC](/funds/1257391.md) | 2026-06-30 | $1.7k | 49,700 | | Unchanged | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $868 | 25,000 | Call | Unchanged | ## Recent filings [All 289 filings](/companies/onmd/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-14 | 12:00 ET | [8-K](/filings/0001493152-26-046931.md) | 8.01 Other events | 0001493152-26-046931 | | 2026-09-29 | 12:30 ET | [8-K](/filings/0001493152-26-044801.md) | 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001493152-26-044801 | | 2026-09-23 | 21:00 ET | [8-K](/filings/0001493152-26-043943.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001493152-26-043943 | | 2026-08-19 | 20:05 ET | [DEF 14A](/filings/0001493152-26-039206.md) | Proxy statement, period 2026-08-19 | 0001493152-26-039206 | | 2026-08-14 | 20:39 ET | [10-Q](/filings/0001493152-26-038461.md) | Quarterly report, period 2026-06-30 | 0001493152-26-038461 | | 2026-07-24 | 21:00 ET | [8-K](/filings/0001493152-26-034599.md) | 5.08 Item not in the standard list; 8.01 Other events | 0001493152-26-034599 | | 2026-07-08 | 20:27 ET | [S-1/A](/filings/0001493152-26-032512.md) | Registration statement, amended | 0001493152-26-032512 | | 2026-07-01 | 21:32 ET | [S-1](/filings/0001493152-26-031598.md) | Registration statement | 0001493152-26-031598 | | 2026-07-01 | 21:20 ET | [8-K](/filings/0001493152-26-031590.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001493152-26-031590 | | 2026-05-15 | 20:16 ET | [10-Q](/filings/0001493152-26-023801.md) | Quarterly report, period 2026-03-31 | 0001493152-26-023801 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-013681.md), filed Mar 30, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/ab3351d8-56e0-4eb0-927c-32edd91cc102) ## About the filer - CIK: 1849380 - Tickers: ONMD, ONMDW - Exchange: Nasdaq - SIC code: 8731 Services-Commercial Physical & Biological Research - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.